Glaukos Co. (NYSE:GKOS) Shares Sold by WCM Investment Management LLC

WCM Investment Management LLC trimmed its position in shares of Glaukos Co. (NYSE:GKOS) by 1.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 97,604 shares of the medical instruments supplier’s stock after selling 1,551 shares during the period. WCM Investment Management LLC owned approximately 0.18% of Glaukos worth $14,593,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in GKOS. Empowered Funds LLC purchased a new position in shares of Glaukos during the 4th quarter valued at approximately $236,000. KBC Group NV boosted its stake in Glaukos by 67.3% during the 4th quarter. KBC Group NV now owns 2,417 shares of the medical instruments supplier’s stock valued at $362,000 after acquiring an additional 972 shares during the last quarter. Zweig DiMenna Associates LLC acquired a new position in Glaukos during the 4th quarter worth $8,796,000. Avior Wealth Management LLC bought a new stake in shares of Glaukos in the 4th quarter worth about $390,000. Finally, SG Americas Securities LLC raised its stake in shares of Glaukos by 42.1% in the 4th quarter. SG Americas Securities LLC now owns 3,641 shares of the medical instruments supplier’s stock valued at $546,000 after purchasing an additional 1,078 shares in the last quarter. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Piper Sandler reissued an “overweight” rating and issued a $180.00 price objective (up from $140.00) on shares of Glaukos in a report on Monday, January 27th. Citigroup upgraded Glaukos from a “neutral” rating to a “buy” rating and boosted their price target for the company from $132.00 to $162.00 in a report on Wednesday, December 11th. Stifel Nicolaus raised their price objective on Glaukos from $153.00 to $175.00 and gave the stock a “buy” rating in a research note on Tuesday, December 31st. UBS Group began coverage on shares of Glaukos in a research note on Friday, December 6th. They set a “buy” rating and a $182.00 target price for the company. Finally, JPMorgan Chase & Co. raised their price target on shares of Glaukos from $130.00 to $145.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Glaukos currently has a consensus rating of “Moderate Buy” and an average target price of $151.08.

Insider Activity at Glaukos

In other news, Director Gilbert H. Kliman sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $150.28, for a total value of $1,502,800.00. Following the completion of the sale, the director now directly owns 32,336 shares of the company’s stock, valued at approximately $4,859,454.08. This represents a 23.62 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Joseph E. Gilliam sold 3,328 shares of the firm’s stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $149.85, for a total transaction of $498,700.80. Following the transaction, the chief operating officer now owns 102,169 shares in the company, valued at $15,310,024.65. This represents a 3.15 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 15,328 shares of company stock worth $2,289,521 in the last three months. 6.40% of the stock is owned by company insiders.

Glaukos Price Performance

NYSE GKOS opened at $153.07 on Monday. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. The company has a 50-day moving average price of $150.69 and a two-hundred day moving average price of $137.34. The stock has a market cap of $8.44 billion, a price-to-earnings ratio of -50.69 and a beta of 1.04. Glaukos Co. has a 52 week low of $83.90 and a 52 week high of $163.71.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.